Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

228954

registered interest
date	23/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Meningitis: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what are the reasons for delays in introducing a vaccine against meningitis B.
tabling member printed	Lord Taylor of Warwick
uin	HL5919
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>The introduction of the meningococcal B vaccine, Bexsero, depends on the outcome of negotiations with the manufacturer for supply at a cost-effective price, as recommended by the Joint Committee on Vaccination and Immunisation. We aim to conclude these negotiations as soon as possible.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 12:56:00 answering member 2000 label Biography information for Earl Howe
tabling member	1796 label Biography information for Lord Taylor of Warwick

228955

registered interest
date	23/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Muscular Dystrophy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what steps they are taking to ensure that the National Health Service supports people with muscular dystrophy.
tabling member printed	Lord Taylor of Warwick
uin	HL5920
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>Through the Mandate we have asked NHS England to make measurable progress towards making our health service among the best in Europe at supporting people with long-term conditions such as muscular dystrophy, to live healthily and independently, with much better control over the care they receive.</p><p> </p><p> </p><p> </p><p>NHS England commissions specialised neurological services at a national level, including for patients with muscular dystrophy. The neurosciences service specifications set out that patients with neuromuscular conditions, such as muscular dystrophy should have access to a multidisciplinary team (MDT) who will assess, diagnose and provide support. The MDT team will include neuromuscular consultants, neuromuscular physiotherapists, specialist nurses, occupational therapists, speech and language therapists and other care professionals. One of the key service outcomes of the specification is that all patients with long-term neurological conditions have an individualised care plan.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 12:58:00 answering member 2000 label Biography information for Earl Howe
tabling member	1796 label Biography information for Lord Taylor of Warwick

228967

registered interest
date	23/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Alcoholic Drinks
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what were the dates of meetings ministers and officials from the Department of Health had with (1) the Portman Group, (2) Drinkaware, (3) Diageo, (4) the Wine and Spirits Trade Association, (5) the British Beer and Pub Association, and (6) SABMiller, between 1 November 2014 and 17 March 2015.
tabling member printed	Lord Avebury
uin	HL5932
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>Dates of meetings attended by the Parliamentary Under Secretary of State for Public Health and officials from the Department:</p><p> </p><p> </p><p> </p><p>- 5 November 2014 – Responsibility Deal alcohol network meeting, attendance included the Portman Group, Diageo, the Wine and Spirits Trade Association, the British Beer and Pub Association and SABMiller;</p><p> </p><p>- 18 November 2014 – Responsibility Deal Plenary Group meeting, attendance included the Portman Group; and</p><p> </p><p>- 3 March 2015 – The All-Party Parliamentary Beer Group reception promoting lower alcohol beers and wines. Attendance included Portman Group, the Wine and Spirits Trade Association, the British Beer and Pub Association and SABMiller.</p><p> </p><p> </p><p> </p><p>Details of meetings held by Ministers and the Permanent Secretary with external organisations are also published quarterly in arrears and can be found at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/collections/ministerial-gifts-hospitality-overseas-travel-and-meetings" target="_blank">https://www.gov.uk/government/collections/ministerial-gifts-hospitality-overseas-travel-and-meetings</a></p><p> </p><p> </p><p> </p><p>Dates of meetings attended by officials from the Department only:</p><p> </p><p> </p><p> </p><p>- 14 November 2014 – Meeting with industry on the EU alcohol strategy, attendance included the Wine and Spirits Trade Association, the British Beer and Pub Association and the Portman Group;</p><p> </p><p>- 4 December 2014 – Drinkaware medical panel meeting;</p><p> </p><p>- 21 January 2015 – Meeting with the Portman Group;</p><p> </p><p>- 3 February 2015 – Drinkaware Board meeting;</p><p> </p><p>- 5 February 2015 – Meeting with the Wine and Spirits Trade Association;</p><p> </p><p>- 16 February 2015 – Meeting with the Portman Group;</p><p> </p><p>- 17 February 2015 – Meeting with the Portman Group;</p><p> </p><p>- 19 February 2015 – Meeting with SABMiller;</p><p> </p><p>- 25 February 2015 – Meeting with the Portman Group;</p><p> </p><p>- 26 February 2015 – Meeting with SABMiller; and</p><p> </p><p>- 26 February 2015 – Meeting with Drinkaware.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 12:59:13 answering member 2000 label Biography information for Earl Howe
tabling member	1665 label Biography information for Lord Avebury

228968

registered interest
date	23/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Alcoholic Drinks: Excise Duties
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what were the dates of meetings ministers and officials from the Department of Health had with public health representatives to discuss the health impacts of potential cuts in alcohol duty between 1 November 2014 and 17 March 2015.
tabling member printed	Lord Avebury
uin	HL5933
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>Ministers and officials in the alcohol policy team meet with public health representatives and experts on a regular basis in the course of their normal activities. Discussions on the general evidence base for the impacts of changes in alcohol duty may have been raised during these meetings. There have been no discussions on specific changes in alcohol duty.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 13:28:45 answering member 2000 label Biography information for Earl Howe
tabling member	1665 label Biography information for Lord Avebury

228976

registered interest
date	23/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmacy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what will be the position of patients, previously served by a dispensing doctor practice, who live within 1.6 km of a pharmacy that closes, but still retains its licence, as a result of the closure of the Essential Small Pharmacies Scheme on 1 April 2015.
tabling member printed	The Countess of Mar
uin	HL5941
answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>The ending of the essential small pharmacy local pharmaceutical services scheme on 31 March 2015 does not require such pharmacies to close. That is a decision for the individual contractor concerned. They may decide to return to the main National Health Service pharmaceutical list and come under the terms of the national community pharmacy contractual framework. Alternatively, they can decide to submit a proposal to NHS England to provide local pharmaceutical services. NHS England is working with individual providers of essential small pharmacies to ensure people in affected communities can continue to access appropriate NHS pharmaceutical services. However, if an essential small pharmacy – or any other type of pharmacy - did decide to close, it would no longer be able to provide NHS pharmaceutical services.</p><p> </p><p> </p><p> </p><p>Patients can at any time request in writing that a doctor provides them with NHS pharmaceutical services. Applications should be made via the doctor to the appropriate NHS England office. To be eligible to receive dispensing services from a doctor, a patient must meet certain criteria, such as having serious difficulty obtaining services from a pharmacy or the patient lives in a designated rural area, more than 1.6 kilometres from the nearest pharmacy. These criteria are set out in Regulation 48 of the National Health Services (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 – SI 2013/349. A patient must also be on the doctor’s patient list, or the patient list of the practice at which the doctor provides or performs primary medical services, and the practice must be authorised by NHS England to provide NHS dispensing services.</p><p> </p> answering member printed Earl Howe question first answered 25/03/2015 16:21:09 answering member 2000 label Biography information for Earl Howe
tabling member	1861 label Biography information for The Countess of Mar

228977

registered interest
date	23/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Orphan Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what steps they are taking to ensure that any decision around ultra-orphan drugs will be referred to the National Institute for Health and Care Excellence Highly Specialised Technologies Evaluation Committee.
tabling member printed	Baroness Masham of Ilton
uin	HL5942
answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>We have referred a number of high cost, low volume technologies to the National Institute for Health and Care Excellence (NICE) for evaluation under its highly specialised technologies work programme. We will continue to do so for technologies that meet the specified criteria and where a NICE evaluation would add value. Further information about the process by which topics are selected for referral to NICE’s highly specialised technologies work programme is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/about/what-we-do/our-programmes/topic-selection" target="_blank">www.nice.org.uk/about/what-we-do/our-programmes/topic-selection</a></p><p> </p> answering member printed Earl Howe question first answered 25/03/2015 13:29:03 answering member 2000 label Biography information for Earl Howe
tabling member	1850 label Biography information for Baroness Masham of Ilton

228683

registered interest
date	19/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Compulsorily Detained Psychiatric Patients
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many places of safety have been provided under section 136 of the Mental Health Act 1983; and what assessment they have made of the geographic spread of such places.
tabling member printed	The Lord Bishop of Bristol
uin	HL5865
answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>The Care Quality Commission has created an interactive web-based map showing the location of designated health-based places of safety in England for people detained under section 136 of the Mental Health Act 1983:</p><p> </p><p><br> <a href="http://www.cqc.org.uk/content/map-health-based-places-safety-0" target="_blank">http://www.cqc.org.uk/content/map-health-based-places-safety-0</a></p><p> </p><p> </p><p> </p><p>The current version shows 167 places of safety in England.</p><p> </p> answering member printed Earl Howe question first answered 25/03/2015 13:29:50 answering member 2000 label Biography information for Earl Howe
tabling member	3892 label Biography information for The Lord Bishop of Bristol

228700

registered interest
date	19/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what recent steps they have taken to improve the diagnosis and management of atrial fibrillation.
tabling member printed	Lord Black of Brentwood
uin	HL5882
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>In 2014, the National Institute for Health and Care Excellence (NICE) published updated guidelines on the management of atrial fibrillation (AF), which covers the diagnosis, assessment and treatment of the condition. NICE is also developing AF Quality Standards which it expects to publish this summer.</p><p> </p><p> </p><p> </p><p>In addition, the NHS Health Check programme’s best practice guidance recommends that a pulse check is carried out as part of the process of taking a blood pressure reading and that individuals who are found to have an irregular pulse rhythm should be referred to their general practitioner (GP) for further investigation.</p><p> </p><p><strong> </strong></p><p> </p><p>NHS Improving Quality’s (NHS IQ) is also taking action on AF. It is promoting the use of GRASP-AF (Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation) within GP practices in England. GRASP-AF is a simple and effective audit tool developed by and trialled in the National Health Service, which greatly simplifies the process of identifying patients with AF who are not receiving the right management to help reduce their risk of stroke. NHS IQ is currently collaborating with partner organisations, including charities, to support the nationwide roll-out of GRASP-AF.</p><p> </p><p> </p><p> </p><p>To support this work, NHS IQ recently published an analysis of the costs and benefits of using the anticoagulant drug warfarin to help prevent stroke in people with AF. A copy of this analysis is attached and can also be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nhsiq.nhs.uk/media/2566750/af_economic_analysis_final.pdf" target="_blank">http://www.nhsiq.nhs.uk/media/2566750/af_economic_analysis_final.pdf</a></p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 12:28:50 answering member 2000 label Biography information for Earl Howe attachment 1 file name Warfarin analysis.pdf title Warfarin costs and benefits analysis
tabling member	4171 label Biography information for Lord Black of Brentwood

228709

registered interest
date	19/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hereditary Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which organisation or body is responsible for assessing the needs of the local population for carrier screening for genetic disorders in at risk populations without an established family history.
tabling member printed	Baroness Deech
uin	HL5891
answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>The UK National Screening Committee makes recommendations on whole population screening programmes. It is for the National Institute for Health and Care Excellence or its accredited guideline producing bodies to recommend care and testing of people at high risk.</p><p> </p><p> </p><p> </p><p>NHS England has commissioning arrangements in place for carrier testing for Tay Sachs disease for at risk populations. Genetic testing will be undertaken where there is a known family history, which indicates a risk of the specific condition or in response to the individual’s clinical symptoms. In the absence of a family history or clinical symptoms it is the responsibility of clinical commissioning groups based on their local needs as to whether they fund referrals to clinical genetics for carrier screening for Tay Sachs disease.</p><p> </p><p> </p><p> </p><p>Genomics offers a great opportunity to improve our insight into genetic diseases. It is for this reason that the Government launched a world-leading project to sequence 100,000 genomes from National Health Service patients and established Genomics England, a subsidiary of the Department, to deliver the project.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5892 HL5893 HL5894 question first answered 25/03/2015 14:05:28 answering member 2000 label Biography information for Earl Howe
tabling member	3756 label Biography information for Baroness Deech

228710

registered interest
date	19/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Tay-Sachs Disease
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of provision in the National Health Service of carrier screening services for Tay Sachs disease in the Ashkenazi Jewish community since the change in national screening policy in April 2013.
tabling member printed	Baroness Deech
uin	HL5892
answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>The UK National Screening Committee makes recommendations on whole population screening programmes. It is for the National Institute for Health and Care Excellence or its accredited guideline producing bodies to recommend care and testing of people at high risk.</p><p> </p><p> </p><p> </p><p>NHS England has commissioning arrangements in place for carrier testing for Tay Sachs disease for at risk populations. Genetic testing will be undertaken where there is a known family history, which indicates a risk of the specific condition or in response to the individual’s clinical symptoms. In the absence of a family history or clinical symptoms it is the responsibility of clinical commissioning groups based on their local needs as to whether they fund referrals to clinical genetics for carrier screening for Tay Sachs disease.</p><p> </p><p> </p><p> </p><p>Genomics offers a great opportunity to improve our insight into genetic diseases. It is for this reason that the Government launched a world-leading project to sequence 100,000 genomes from National Health Service patients and established Genomics England, a subsidiary of the Department, to deliver the project.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5891 HL5893 HL5894 question first answered 25/03/2015 14:05:28 answering member 2000 label Biography information for Earl Howe
tabling member	3756 label Biography information for Baroness Deech